Synthetic Platforms

SNAP for tolerance (e.g. autoimmunity)

Importantly, SNAP’s modular design has enabled discovery of a lead SNAP Tolerance Immunotherapy (SNAP-TI) that is designed to induce regulatory T cells (“Tregs”) and mitigates disease in a mouse model of multiple sclerosis (EAE). Based on its capacity to induce Tregs promoting tolerance we are advancing SNAP-TI as a versatile platform for treating inflammatory diseases with initial clinical proof-of-concept being pursued in celiac disease.

SNAP for cancer

Our recent publications in Nature Biotechnology and Nature Immunology describe how the SNAP Cancer Immunotherapy (SNAP-CI) was systematically optimized to codeliver immunostimulants and tumor antigens for inducing high magnitude cytotoxic T cells for treating cancer. Preclinical studies have shown that efficacy with SNAP-CI is further enhanced when used in combination with our ChAdOx platform.

SNAP’s differentiating advantages

  • Potential therapeutic opportunities enabled by modular design allowing for programmable induction of cytotoxic T cells for cancer or Tregs for tolerance.
  • Synthetic platform may increase breadth of targets for the immune system, such as post-translationally modified antigens inaccessible to RNA and viral vaccines.
  • Repeatable administration by any route may assist in sustaining T cell responses.